Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 15/20 | 0.64 |
| ▸ | PIK3CB | P42338 | 15/20 | 0.64 |
| ▸ | PIK3CG | P48736 | 15/20 | 0.64 |
| ▸ | PIK3CA | P42336 | 14/20 | 0.64 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1750491 | 0.90 | PIK3CD (0.53) | PIK3CDPIK3CBPIK3CGPIK3CACSNK2A1 | |
| SCHEMBL296157 | 0.83 | PIK3CD (0.70) | PIK3CDPIK3CBPIK3CGPIK3CACSNK2A1 | |
| SCHEMBL301173 | 0.81 | PIK3CD (0.65) | PIK3CDPIK3CBPIK3CGPIK3CACSNK2A1 | |
| SCHEMBL30662742 | 0.81 | PIK3CD (0.65) | PIK3CDPIK3CBPIK3CGPIK3CACSNK2A1 | |
| SCHEMBL300868 | 0.81 | PIK3CD (0.71) | PIK3CDPIK3CBPIK3CGPIK3CACSNK2A1 | |
| SCHEMBL11939631 | 0.81 | PIK3CD (0.82) | PIK3CDPIK3CBPIK3CGPIK3CACSNK2A1 | |
| SCHEMBL293199 | 0.80 | PIK3CD (0.68) | PIK3CDPIK3CBPIK3CGPIK3CACSNK2A1 | |
| SCHEMBL4047082 | 0.80 | PIK3CD (0.70) | PIK3CDPIK3CBPIK3CGPIK3CACSNK2A1 | |
| SCHEMBL300894 | 0.79 | PIK3CD (0.71) | PIK3CDPIK3CBPIK3CGPIK3CACSNK2A1 | |
| SCHEMBL300847 | 0.79 | PIK3CD (0.71) | PIK3CDPIK3CBPIK3CGPIK3CACSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2078018-B1 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND USE THEREOF AS PROTEIN KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2012-03-14 | — | — | EP | claimed |
| CN-107976546-B | Inhibition of phosphorylation of TOR kinase inhibitory Activity markers PRAS40, GSK 3-beta, or P70S6K1 | 西格诺药品有限公司 | 2020-10-27 | — | — | CN | disclosed |
| CN-110721186-A | Treatment of prostate cancer with TOR kinase inhibitors | 西格诺药品有限公司 | 2020-01-24 | — | — | CN | disclosed |
| CN-107157990-B | Treatment of cancer with TOR kinase inhibitors | 西格诺药品有限公司 | 2020-01-07 | — | — | CN | disclosed |
| CN-109846884-A | With TOR kinase inhibitor for treating cancer | 西格诺药品有限公司 | 2019-06-07 | — | — | CN | disclosed |
| US-9555033-B2 | Identification of LKB1 mutation as a predictive biomarker for sensitivity to TOR kinase inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2017-01-31 | — | — | US | disclosed |
| US-9493466-B2 | Treatment of cancer with TOR kinase inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2016-11-15 | — | — | US | disclosed |
| US-20140113904-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-04-24 | — | — | US | disclosed |
| US-20130245026-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130245027-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130245029-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130245028-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130158023-A1 | IDENTIFICATION OF GENE EXPRESSION AS A PREDICTIVE BIOMARKER FOR LKB1 STATUS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130102613-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-04-25 | — | — | US | disclosed |
| US-8383634-B2 | Methods of treatment using heteroaryl compounds and compositions thereof | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-02-26 | — | — | US | disclosed |
| US-20110257167-A1 | IDENTIFICATION OF LKB1 MUTATION AS A PREDICTIVE BIOMARKER FOR SENSITIVITY TO TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC | 2011-10-20 | — | — | US | disclosed |
| US-20110224217-A1 | METHODS OF TREATMENT USING HETEROARYL COMPOUNDS AND COMPOSITIONS THEREOF | SIGNAL PHARMACEUTICALS, LLC | 2011-09-15 | — | — | US | disclosed |
| US-7968556-B2 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2011-06-28 | — | — | US | disclosed |
| US-20090042890-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245027-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | MTOR, TTK, BRCA1 | PIK3CD 83/4885PIK3CB 85/4885PIK3CG 104/4885 |
| US-20110257167-A1 | IDENTIFICATION OF LKB1 MUTATION AS A PREDICTIVE BIOMARKER FOR SENSITIVITY TO TOR KINASE INHIBITORS | STK11, STK16, STK10 | PIK3CD 354/4885PIK3CB 343/4885PIK3CG 392/4885 |
| US-20130245026-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | MTOR, CHEK2, CHEK1 | PIK3CD 111/4885PIK3CB 109/4885PIK3CG 150/4885 |
| US-20110224217-A1 | METHODS OF TREATMENT USING HETEROARYL COMPOUNDS AND COMPOSITIONS THEREOF | JAK2, CHEK2, PHKG1 | PIK3CD 649/4885PIK3CB 267/4885PIK3CG 821/4885 |
| US-20130158023-A1 | IDENTIFICATION OF GENE EXPRESSION AS A PREDICTIVE BIOMARKER FOR LKB1 STATUS | STK16, STK10, STK11 | PIK3CD 684/4885PIK3CB 650/4885PIK3CG 1076/4885 |
| US-20130102613-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | MTOR, TTK, RICTOR | PIK3CD 98/4885PIK3CB 90/4885PIK3CG 120/4885 |
| US-20130245029-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | EWSR1, ELF3, MTOR | PIK3CD 173/4885PIK3CB 114/4885PIK3CG 180/4885 |
| US-20130245028-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | ELF3, ERG, MTOR | PIK3CD 175/4885PIK3CB 141/4885PIK3CG 193/4885 |
| US-20140113904-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | MTOR, TTK, TNNI3K | PIK3CD 157/4885PIK3CB 145/4885PIK3CG 189/4885 |
| US-20090042890-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | JAK2, CHEK2, SRC | PIK3CD 569/4885PIK3CB 267/4885PIK3CG 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.